T. Schneider / Shutterstock.com
20 February 2025NewsAmericasMarisa Woutersen

Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules

British pharma giant says that a Federal Circuit decision could stifle competition by lowering the bar for proving patent infringement | Earlier ruling ‘nullifies a statutory mechanism for expediting access to generic drugs and breaks sharply with precedent on inducement’ says UK pharma company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
27 June 2024   Judges considered Hikma’s label and marketing material when overturning lower court’s decision | Court said Amarin had stated plausible claim for induced infringement of patents.
Big Pharma
23 March 2023   Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

More on this story

Americas
27 June 2024   Judges considered Hikma’s label and marketing material when overturning lower court’s decision | Court said Amarin had stated plausible claim for induced infringement of patents.
Big Pharma
23 March 2023   Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

More on this story

Americas
27 June 2024   Judges considered Hikma’s label and marketing material when overturning lower court’s decision | Court said Amarin had stated plausible claim for induced infringement of patents.
Big Pharma
23 March 2023   Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.